Skip to main
MNOV

MediciNova (MNOV) Stock Forecast & Price Target

MediciNova (MNOV) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MediciNova Inc. demonstrates a strong outlook due to its continued advancement in late-stage programs for treatments targeting progressive multiple sclerosis and degenerative cervical myelopathy, which could enhance visibility and potential market relevance. The positive clinical developments for its therapeutics, including MN-166’s supportive profile in neuroprotection and MN-001’s differentiation in treating hepatic fibrosis and potential expansion into metabolic diseases, underscore the company's strategic focus on addressing significant unmet medical needs. Additionally, successful achievements in enrollment goals for clinical trials, despite disruptions, reflect MediciNova's commitment to leveraging partnerships and funding to efficiently advance its diversified pipeline, positioning the company favorably within the biopharmaceutical landscape.

Bears say

The excerpt indicates that MediciNova may have achieved a high level of study rigor, eliminating potential biases in its clinical trials; however, this does not address underlying financial concerns such as potential high R&D costs and the risks associated with drug development. Additionally, the firm remains focused on niche therapeutic areas, which could limit its market potential and revenue growth, particularly amidst a competitive landscape in biopharmaceuticals. Overall, uncertainties surrounding successful product commercialization and ongoing financial obligations may contribute to a negative outlook for MediciNova's stock.

MediciNova (MNOV) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MediciNova and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MediciNova (MNOV) Forecast

Analysts have given MediciNova (MNOV) a Strong Buy based on their latest research and market trends.

According to 2 analysts, MediciNova (MNOV) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MediciNova (MNOV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.